Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission-Reference-Cited by-同舟云学术

Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission

Published:2020-06-26 Issue:8 Volume:111 Page:2923-2934
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kumagai Takashi¹^ORCID,Nakaseko Chiaki²,Nishiwaki Kaichi³,Yoshida Chikashi⁴,Ohashi Kazuteru⁵,Takezako Naoki⁶,Takano Hina⁷,Kouzai Yasuji⁸,Murase Tadashi⁹,Matsue Kosei¹⁰^ORCID,Morita Satoshi¹¹,Sakamoto Junichi¹²,Wakita Hisashi¹³,Sakamaki Hisashi⁵,Inokuchi Koiti¹⁴,

Affiliation:

1. Department of Hematology Ome Municipal General Hospital Tokyo Japan

2. Department of Hematology Chiba University Hospital Chiba Japan

3. Division of Clinical Oncology and Hematology Department of Internal Medicine Jikei University School of Medicine Kashiwa Hospital Chiba Japan

4. Department of Hematology National Hospital Organization Mito Medical Center Higashiibarakigun Japan

5. Hematology Division Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

6. Department of Hematology National Hospital Organization Disaster Medical Center Tachikawa Japan

7. Department of Hematology Musashino Red Cross Hospital Musashino Japan

8. Department of Hematology Tokyo Metropolitan Tama Synthesis Medical Center Tokyo Japan

9. Department of Laboratory Medicine Dokkyo Medical University Koshigaya Hospital Saitama Japan

10. Division of Hematology/Oncology Department of Internal Medicine Kameda Medical Center Kamogawa Japan

11. Department of Biomedical Statistics and Bioinformatics Kyoto University Graduate School of Medicine Kyoto Japan

12. Tokai Central Hospital Kakamigahara Japan

13. Division of Hematology and Oncology Japanese Red Cross Society Narita Red Cross Hosp Narita Japan

14. Department of Hematology Nippon Medical School Tokyo Japan

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14518

Reference39 articles.

1. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

2. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

3. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

4. Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival

5. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation;Leukemia;2023-11-02

3. A Gut Instinct on Leukaemia: A New Mechanistic Hypothesis for Microbiota-Immune Crosstalk in Disease Progression and Relapse;Microorganisms;2022-03-25

4. Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients;Expert Review of Hematology;2021-12-27

5. Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells;Frontiers in Oncology;2021-10-28